Bruce M Wexler

Partner, Litigation Department

New York

T 1(212) 318-6020

F 1(212) 230-7644

Bruce Wexler is a partner and Chair of the Life Sciences Industry Practice Group at Paul Hastings. Mr. Wexler is a trial lawyer with extensive experience litigating high-stakes patent cases in a range of technologies. He has represented clients as lead counsel defending their patents covering multi-million and multi-billion dollar drug products.

Mr. Wexler is also an Adjunct Professor of Law at New York University School of Law, where he teaches an advanced course in “Life Sciences Patent Law.”

AWARDS AND ACCOLADES

Chambers USA 2017 says Bruce Wexler is “very, very talented and a very bright guy” who is praised by sources for the way in which he “comes up with creative and effective solutions to situations.” He represents pharmaceutical companies in high-stakes litigation, where “he not only thinks of the grand design but is also very good tactically.”
The Intellectual Asset Management’s IAM Patent 1000 (2017) report refers to him as a “wonderfully gifted lawyer” and “Wexler is phenomenally prepared- there is nobody better at digging into the facts. He is a big picture thinker with excellent presentation skills.”
LMG Life Sciences heralded Mr. Wexler as a “preeminent litigator in the industry” and recognized him as General Patent Litigator of the Year – New York for 2016. His representation of Eli Lilly was also honored by LMG as Hatch-Waxman Impact Case of the Year. He was also a nominee for General Patent Litigator of the Year – New York in 2017.
The American Lawyer’s 2015 Transatlantic Lawyer of the Year – IP
Winner of 2015 Client Choice Award
Ranked in Chambers Global 2015, USA, Intellectually Property: Patent
Chambers USA calls Mr. Wexler a “litigation and trial expert at the firm,” noting his ability to “explain complex situations clearly to enable informed decision-making” and his “exceptional writing skills and strong technical ability.”
In its 2015 IP Stars nationwide analysis, Managing Intellectual Property identified Mr. Wexler as a “fantastic lawyer,” a “standout attorney,” and a “well-respected leader in the field.” Mr. Wexler was named one of the “preeminent litigators in the industry” by LMG Life Sciences Guide and has been a Life Science nominee for Litigator of the Year.
The Intellectual Asset Management’s IAM Patent 1000 (2012) report refers to him as an “awesomely effective trial lawyer.”
Ranked in IAM Patent 1000's (2013) survey’s Gold band identifying him as the "crème de la crème" for Litigation by reputation and work on the most high-profile, big-ticket work from the most demanding of clients. According to IAM, Mr. Wexler “takes a robust yet reasonable approach to litigation” and is noted by source as “performing at his best in highly charged contentious scenarios.”
The Financial Times awarded his successful defense of the Aricept® drug franchise a “standout” notice for innovative lawyering.
He is recognized in the IAM250 leading New York IP Litigators report as a “really strong substantive lawyer.” He is ranked in The Legal 500 US and featured as a NY “Super Lawyer.” The Legal 500 notes that Mr. Wexler has "extensive patent litigation experience, with strategic considerations and observations being very sophisticated and right to the point" and that he is "splendid at trial."
Mr. Wexler is a recipient of the Burton Award for Legal Achievement in writing.

Experience

Merck Sharp & Dohme Corp. v. Sandoz Inc. and Accord Healthcare, Inc.

Mr. Wexler served as lead counsel for Merck in patent infringement litigation defending Merck’s patent protecting the active ingredient in Emend® for Injection, an important drug for the prevention of chemotherapy-induced nausea and vomiting. After a six-day bench trial, Judge Sheridan of the District of New Jersey entered judgment in favor of Merck on all aspects of Sandoz’s invalidity defenses, resulting in a complete victory for Merck. In the course of the Court’s 80-page opinion finding in Merck’s favor, the Court noted the lack of credibility of Sandoz’s key expert witness who had been cross-examined by Mr. Wexler.
Sanofi-Aventis US LLC et al. v. Eli Lilly & Co.

Mr. Wexler served as lead counsel for Eli Lilly & Co. in litigation with Sanofi regarding Eli Lilly’s request to market its insulin glargine drug product Basaglar®. Sanofi brought suit on five patents, relating to a pharmaceutical composition and injector pen device, listed in the FDA Orange Book for Sanofi’s Lantus® and Lantus SoloStar® insulin glargine products. Mr. Wexler successfully led the case through fact and expert discovery, including live-witness Markman proceedings, obtaining important claim construction rulings pertaining to the patents in suit. The case settled on the eve of trial in late 2015 with the press reporting Eli Lilly’s ability to launch Basaglar® the following year.
Eisai Inc. and Eisai Co., Ltd. v. Glenmark Generics, Ltd., Hetero Labs, Ltd., Lupin Pharmaceuticals, Inc., Mylan Pharmaceuticals, Inc., and Roxane Laboratories, Inc., et al.

Mr. Wexler was lead counsel for Eisai in litigation with five generic defendant groups involving the patents directed to a crystalline form of rufinamide, the active ingredient in Eisai’s drug product, Banzel®, an important drug in the treatment of epilepsy. After successfully litigating through fact and expert discovery, Mr. Wexler obtained a victory in Markman proceedings having significant implications for the infringement and validity issues in the case. Mr. Wexler also convinced the Court, during the final pretrial conference, to exclude certain purported testing evidence by the defendants offered in support of their invalidity defense. The case finally settled on favorable terms an hour before opening arguments at trial.
Merck Sharp & Dohme Corp. v. Apotex Inc.

While district court litigation was ongoing with other generic drug companies, generic drug company Apotex filed a petition for Inter Partes Review (IPR) at the U.S. Patent and Trademark Office seeking to invalidate the patent protecting Merck’s Emend® for Injection drug product. Together with Paul Hastings partner Naveen Modi, Mr. Wexler obtained a successful ruling from the PTO rejecting Apotex’s invalidity attack and refusing to institute review, and this ruling was subsequently reaffirmed on Apotex’s petition for rehearing.
Boehringer Ingelheim International GmbH and Boehringer Ingelheim Pharmaceuticals, Inc. v. Mylan Pharmaceuticals, Inc.

Mr. Wexler was lead counsel for Boehringer Ingelheim in this appeal involving the patent protecting Mirapex®, a key drug in the treatment of Parkinson’s disease. Mr. Wexler was hired to handle the appeal after another firm had received an adverse ruling at trial. Mr Wexler argued and won a complete reversal from the Federal Circuit, with the Court declaring the patent to be valid. The appeal established important precedent concerning the scope of the double patenting safe harbor provision, 35 U.S.C. 121.
Sandoz Inc. v. Boehringer Ingelheim International GmbH and Boehringer Ingelheim Pharmaceuticals, Inc.

Mr. Wexler was lead trial counsel for Boehringer Ingelheim in its counterclaim action for patent infringement against Sandoz. Mr. Wexler argued and won a preliminary injunction ruling, delivered from the bench, preventing Sandoz from launching a generic version of Mirapex®. The court was persuaded to grant the injunction on a patent that had been subject to a license and which would be expiring in several months. The judge deciding this case had, in his immediately preceding patent case, refused both preliminary and permanent injunctive relief in part on the ground that the patentee had previously licensed the patent. Mr. Wexler subsequently negotiated a stipulation continuing the injunction through patent expiration.
Takeda Pharmaceutical Company Ltd. and Takeda Pharmaceuticals North America Inc. v. Teva Pharmaceuticals USA, Inc. and Watson Laboratories Inc.

Mr. Wexler was lead trial counsel for Takeda in two actions enforcing Takeda’s patent for its anti-insomnia drug Rozerem® against challenge by generic drug companies Teva and Watson. After two years of litigation through fact and expert discovery, Mr. Wexler obtained a favorable settlement dismissing both companies’ patent challenges.
Eisai Co., Ltd. and Eisai Inc. v. Teva Pharmaceuticals USA, Inc.

Mr. Wexler was lead trial counsel for Eisai in an action defending Eisai’s patent protecting Aricept®, the market leading drug for the treatment of Alzheimer’s disease, having sales of some $2 billion/year. Mr. Wexler obtained a preliminary injunction against Teva’s threatened launch of a generic version of the drug. Mr. Wexler ensured continued exclusivity of the patent through patent expiration, and successfully defended attempts by Teva to trigger and run out the regulatory exclusivity of a first-filing generic drug applicant.
Merck & Co., Inc. v. Sandoz Inc.

Mr. Wexler was lead trial counsel for Merck in an action enforcing Merck’s patents protecting its oral anti-emetic drug product, Emend®. Mr. Wexler ultimately obtained a consent judgment for his client that included an injunction prohibiting Sandoz from infringement through patent expiration.
Eisai Co., Ltd. and Eisai Inc. v. Teva Pharmaceuticals USA, Dr. Reddy’s Laboratories and Mylan Laboratories

Mr. Wexler was co-lead trial counsel to Eisai in litigation defending Eisai’s patent covering Aciphex®, an acid reflux drug with annual US sales in excess of $1 billion. Mr. Wexler and his partner Joe O’Malley initially won summary judgment for Eisai of patent validity. They subsequently succeeded at trial in defeating Teva’s and Dr. Reddy’s charges of inequitable conduct, and obtained affirmance of that judgment on appeal. The case established helpful precedent for innovator pharmaceutical companies with respect to the standards for judging obviousness of a compound patent.
Nycomed v. Teva Pharmaceuticals USA, Inc.

Mr. Wexler represented Wyeth (acquired by Pfizer) and Altana Pharma AG (acquired by Nycomed) in a jury trial against three generic pharmaceutical companies regarding the companies’ $2 billion per year ulcer drug Protonix®. The jury upheld the validity of the patent, permitting the plaintiffs to seek recovery of damages caused by an at-risk generic drug launch.
Apotex Inc. v. Eisai Co., Ltd. and Eisai Inc.

Mr. Wexler was lead counsel for Eisai defending a declaratory judgment action by Apotex alleging that its generic product did not infringe four Eisai patents relating to Aricept®. In August 2010, in a lengthy opinion analyzing the Hatch-Waxman Act legal framework, Mr. Wexler obtained a dismissal of the action, effectively preventing Apotex from triggering and running out a regulatory exclusivity prior to the expiration of Eisai’s basic patent covering Aricept®.
Warner-Lambert Company v. Teva Pharmaceuticals USA, Inc.

Mr. Wexler represented Pfizer (Warner-Lambert Company) during a successful bench trial against Teva involving Pfizer’s formulation patent covering its highly successful cardiovascular drug Accupril®. In its decision, the Court found the patent was not invalid for lack of enablement, despite the breadth of the claims. With that trial decision, all issues of infringement, enforceability and validity were decided in Pfizer’s favor in the case after eight years of litigation. The case then settled while the appeal of the enablement ruling was pending.

Speaking Engagements and Publications

Mr. Wexler’s writing has been published in numerous journals, including Forbes, Law360, IP Magazine, Managing IP, and NYU’s Journal of Intellectual Property and Entertainment Law.
He is a regular speaker at legal seminars, including ACI’s Paragraph IV Disputes conference.
Mr. Wexler has been quoted frequently with regard to litigation and practice developments, including in the Wall Street Journal, Bloomberg News, Reuters, The Deal and The New York Times.
Mr. Wexler regularly provides his clients with in-house CLE presentations on a variety of topics of interest, and authors client alerts concerning important developments in the law.

Professional and Community Involvement

Mr. Wexler advised Congress and key stakeholders during the consideration and enactment of the America Invents Act.
He is a former judicial law clerk of the U.S. Court of Appeals for the Federal Circuit, where he served under Chief Judge Glenn L. Archer, Jr. He clerked for Chief Judge Archer during the Chief Judge’s preparation of influential Federal Circuit decisions including Markman v. Westview.

Education

New York University School of Law, J.D. (magna cum laude, Order of the Coif)
Rensselaer Polytechnic Institute, B.S. in Physics (summa cum laude, member - Sigma Pi Sigma honor society)

Rankings & Awards

Recognized by Managing IP as the Life Sciences IP Litigation Firm of the Year
Paul Hastings was was recognized by Managing IP at their Americas Awards, which honored individuals and companies behind the most innovative and challenging IP work of the past year, as well as those driving the international IP market. The firm was recognized as Life Sciences IP Litigation Firm of the Year in the United States.
April 05, 2019

Recognized by Chambers Global 2019
Chambers Global 2019: The World’s Leading Lawyers listed the firm in 37 research areas and named 59 firm lawyers to its rankings of leading lawyers and law firms adept in complex international work and with strong cross-border capabilities.
February 14, 2019

Recognized as the 2019 Post-Grant Firm of the Year by IAM Magazine
Paul Hastings was recognized as the Post-Grant Firm of the Year at Intellectual Asset Management's inaugural Global IP Awards. The award recognizes the achievements of the firm's Patent Trial and Appeal Board (PTAB) Team, which practices before the US Patent & Trial Office. Over the past year, the team's accomplishments include numerous post-grant proceeding victories for technology and life sciences clients - four of which were affirmed by the Court of Appeals for the Federal Circuit.
January 30, 2019

Recognized as LMG Life Sciences Stars for 2018
Paul Hastings was recognized in the 2018 edition of LMG Life Sciences, with Highly Recommended rankings for General Patent Litigation and Hatch-Waxman Branded Litigation. LMG Life Sciences selected seven individual lawyers as "Life Sciences Stars," including Eric Dittmann, Gary Giampetruzzi, Naveen Modi, Joseph O’Malley, Chad Peterman, Preston Ratliff, and Bruce Wexler. Earlier this year, LMG Life Sciences honored the firm with the LMG Life Sciences award for Hatch-Waxman Litigation Firm of the Year – Branded.
October 12, 2018

Recognized as the Hatch-Waxman Litigation Firm of the Year by LMG Life Sciences
LMG Life Sciences announced that the firm’s Intellectual Property practice was honored at the LMG Life Sciences Awards as the Hatch-Waxman Litigation Firm of the Year (Branded). The publication cited the firm for wins on behalf of Sunovion Pharmaceuticals, which locked in compound patent protection for Latuda®, the company’s billion-dollar-plus-per-year schizophrenia and bipolar drug, after a judgment of infringement that was affirmed by the Federal Circuit; and for Orexigen Therapeutics after a trial victory where the judge found all three patents-in-suit to be valid and infringed. The firm was also noted for obtaining an unprecedented six walk-away consent judgments in a major pharmaceutical litigation.

The firm and its partners were also shortlisted for:
* Inter-Partes Review Firm of the Year
* Post Grant Proceedings Attorney of the Year: Naveen Modi
* General Patent Litigator of the Year – New York: Bruce Wexler
September 13, 2018

Recognized as the Transatlantic IP Team of the Year by The American Lawyer
The American Lawyer named Paul Hastings its Transatlantic IP Team of the Year at the Transatlantic Legal Awards. The practice was honored due to Bruce Wexler, Eric Dittmann, and Isaac Ashkenazi leading a team in a major pharmaceutical litigation through fact, expert and Markman phases, and obtaining six walk-away consent judgments.
The awards consider the top legal work between the U.S. and the U.K. and European legal markets, recognizing law firms for “excellence in handling transatlantic matters across the key areas of corporate, finance, and disputes, as well as highlighting law firm innovation, commitment to pro bono, outstanding transatlantic strategy, and in-house leaders.”
June 15, 2018

Recognized by Chambers USA 2018
Chambers USA 2018: America’s Leading Lawyers for Business listed the firm in 45 research areas and named 112 firm lawyers to its rankings of leading lawyers and law firms in the United States.
May 15, 2018

Recognized as Law360 Practice Group of the Year in Life Sciences
Paul Hastings was named as a Practice Group of the Year in Life Sciences by Law360. The article noted Paul Hastings’ undefeated track record in life sciences cases at the Patent Trial and Appeal Board, including victories on behalf of Acorda Therapeutics, which won four inter partes reviews against Kyle Bass’ Coalition for Affordable Drugs. Law360 also highlighted the representation of Galena Biopharma in a civil-only settlement resolving investigations regarding Galena’s past promotional practices for Abstral, a rapid onset opioid product. The winners were chosen from nearly 750 submissions, and are recognized as "firms that racked up victories in litigation and closed the big deals to make their mark among clients and throughout the legal industry."
February 01, 2018

Recognized as LMG Life Sciences Stars for 2017
Paul Hastings was recognized in LMG Life Sciences, with Highly Recommended rankings for General Patent Litigation and Hatch-Waxman Branded Litigation. LMG Life Sciences selected seven individual lawyers as "Life Sciences Stars," including Joseph O’Malley, Bruce Wexler, Gerald Flattmann, Naveen Modi, Chad Peterman, Eric Dittmann, and Gary Giampetruzzi.
October 06, 2017

Paul Hastings IP Practice Honored in 2017 IAM Patent 1000
Intellectual Asset Management highlighted Paul Hastings' IP practice in IAM Patent 1000: The World's Leading Patent Professionals. The guide ranked the firm's practices Nationwide as well as in New York and Washington, DC. Paul Hastings partners were ranked in California: Yar Chaikovsky; New York: Joseph O'Malley; Gerald Flattmann; Preston Ratliff; Bruce Wexler; Samuel Waxman; Washington DC: Naveen Modi; Blair Jacobs; Joseph Palys; and Allan Soobert; and in Japan: Hiroyuki Hagiwara.

Paul Hastings attorneys were also recognized in IAM's Nationwide tables: Yar Chaikovsky and Blair Jacobs were recommended for International Trade Commission litigation; Jacobs was recommended for his experience in Federal Circuit appellate litigation; and Naveen Modi and Joseph Palys were both recognized for their strength in post-grant proceedings. Preston Ratliff was also noted in the IAM Strategy 300, which recognizes individuals for their work in protecting intellectual property as a key business asset.
June 06, 2017

Recognized by Chambers USA 2017
Chambers USA 2017: America’s Leading Lawyers for Business named 46 of the firm’s practice areas and 112 individuals to its ranking of leading lawyers and law firms in the United States.
June 05, 2017

Recognized as LMG Life Sciences Stars for 2016
Paul Hastings was recognized in LMG Life Sciences, with Highly Recommended rankings for General Patent Litigation and Hatch-Waxman Branded Litigation. LMG Life Sciences selected six individual lawyers as "Life Sciences Stars," including Joseph O’Malley, Bruce Wexler, Gerald Flattmann, Gary Giampetruzzi, Naveen Modi, and Eric Dittmann.
November 30, 2016

Benchmark Litigation 2017
Benchmark Litigation recognized Yar Chaikovsky, Gerald Flattmann, Douglas Flaum, Holly House, Joseph O'Malley, Barry Sher, Peter Stone, William Sullivan, Bruce Wexler, William K. Whitner, and Thomas Zaccaro as Litigation Stars in its 2017 guide, which focuses exclusively on litigation in the United States. The guide is the result of six months of research, including extensive interviews with litigators and clients as well as a close examination of recent casework handled by the firm. The firm was ranked in Tier 1 for U.S. Intellectual Property and as Highly Recommended in California.
October 21, 2016

Recognized at the 2016 LMG Life Sciences Awards
Paul Hastings was recognized with multiple LMG Life Sciences Awards. Bruce Wexler was named “General Patent Litigator of the Year – New York” and Naveen Modi was recognized as Post Grant Proceedings Attorney of the Year. The Life Sciences Patent Litigation practice also won awards for two Hatch-Waxman Impact Cases of the Year, including Helsinn Healthcare SA v. Teva Pharmaceuticals USA, a win resolving a long-running patent dispute over Aloxi®, a drug used to treat chemotherapy-induced nausea and vomiting. The Paul Hastings team representing Helsinn was led by Joseph O’Malley. The firm was also honored for its work on behalf of Eli Lily in Sanofi-Aventis US v. Eli Lilly & Co., where Bruce Wexler led the team representing Eli Lily in litigation regarding the marketing of Basaglar®, its insulin glargine drug product. The case was settled in late 2015, with the press reporting Eli Lilly’s ability to launch the drug.
September 16, 2016

Shortlisted for four LMG Life Sciences Awards for 2016
The Firm was shortlisted in four categories for the LMG Life Sciences Awards. Joseph O’Malley was nominated in the Hatch-Waxman Litigator of the Year – Branded category, Bruce Wexler was nominated in the General Patent Litigator of the Year - New Yorkcategory, Naveen Modi was nominated in the Post Grant Proceedings Attorney of the Year category, and the Firm was nominated in the “Hatch-Waxman Litigation Firm of the Year – Branded” category.
July 27, 2016

The American Lawyer's Transatlantic Lawyer of the Year: Intellectual Property
The American Lawyer named Bruce Wexler the Transatlantic Lawyer of the Year: Intellectual Property at its Transatlantic Legal Awards 2016. These awards consider the top legal work between the U.S. and the U.K. and European legal markets, recognizing law firms for “excellence in handling transatlantic matters across the key areas of corporate, finance, and disputes, as well as highlighting law firm innovation, commitment to pro bono, outstanding transatlantic strategy, and in-house leaders.” The winners were announced at a gala dinner in London on June 7, 2016, jointly hosted by The American Lawyer and Legal Week.
June 10, 2016

Recognized by Chambers USA 2016
Chambers USA 2016: America’s Leading Lawyers for Business named 47 of the firm’s practice areas and 112 individuals to its ranking of leading lawyers and law firms in the United States.
June 08, 2016

Paul Hastings IP Practice Honored in 2016 IAM Patent 1000
Intellectual Asset Management highlighted Paul Hastings' IP practice in its IAM Patent 1000: The World’s Leading Patent Professionals 2016. The guide ranked the firm’s Nationwide, New York, Washington, D.C., and Georgia IP practices; and partners Yar Chaikovsky, Gerald Flattmann, Blair Jacobs, Robin McGrath, Naveen Modi, Joseph O'Malley, Joseph Palys, Preston Ratliff, Samuel Waxman, and Bruce Wexler were recognized as leading lawyers.
May 27, 2016

Benchmark Litigation 2016

Benchmark Litigation recognized Yar Chaikovsky, Gerald Flattmann, Douglas Flaum, Holly House, Joseph O'Malley, Barry Sher, Peter Stone, William Sullivan, Bruce Wexler, and William K. Whitner as Litigation Stars in its 2016 guide, which focuses exclusively on litigation in the United States and is the result of six-months of research that includes extensive interviews with litigators, clients and a close examination of recent casework handled by the firm. The firm was ranked as Highly Recommended in California, and in Tier 2 for US Intellectual Property.

Additionally, the firm was shortlisted for the 2016 Benchmark Litigation US Awards in the State Firm Awards – California category, and Yar Chaikovsky was shortlisted in the Practice Area Attorneys of the Year – Intellectual Property category.

December 09, 2015

Paul Hastings IP Practice Honored in 2015 IAM Patent 1000
Intellectual Asset Management highlighted Paul Hastings' IP practice in its IAM
Patent 1000: The World’s Leading Patent Professionals 2015. The guide ranked the firm’s Nationwide, New York, and Washington, D.C. IP practices; and partners Yar Chaikovsky, Gerald Flattmann, Blair Jacobs, Naveen Modi, Joseph O'Malley, Steven Park, Jeff Randall, Preston Ratliff, Allan Soobert, and Bruce Wexler were recognized as leading lawyers.
June 17, 2015

Managing IP's 2015 IP Stars
Yar Chaikovsky, Gerald Flattmann, Blair Jacobs, Chris Kennerly, Naveen Modi, Joseph O'Malley, and Bruce Wexler were named 2015 IP Stars by Managing Intellectual Property magazine. Nationwide, the firm's Intellectual Property practice was ranked in the Bio/Life Sciences, Copyright, and Patent Contentious categories. In New York, the firm was ranked Highly Recommended in the Patent Contentious category, and in California, the firm was ranked Recommended in the Copyright and Patent Contentious categories.
May 15, 2015

Recognized by LMG Life Sciences for Life Sciences IP Litigation
Paul Hastings' Life Sciences Intellectual Property practice received the highest possible ranking in Legal Media Group’s Life Sciences 2014 guide; as it was ranked “Highly Recommended” in the Hatch-Waxman Patent Litigation (Branded) and General Patent Litigation categories. Commentary from the guide singled out Joseph O’Malley and Bruce Wexler as “preeminent litigators in the industry” and pointed out Gerald Flattmann’s "ability to serve as lead counsel in important industry cases." The IP practice was also described as having “outstanding teams both for commercial patent litigation as well as in dealing with infringement suits on the branded Hatch-Waxman front.”
October 09, 2014

Paul Hastings Intellectual Property Practice Honored in IAM Patent 1000

Intellectual Asset Management highlighted Paul Hastings IP practice in its 2014 Patent 1000 guide to the top patent practitioners. The guide ranked the firm’s Nationwide and New York IP practices; and partners Gerald Flattmann, Joseph O’Malley, Steven Park, Jeff Randall, Allan Soobert and Bruce Wexler were recognized as leading patent lawyers.

June 05, 2014

Managing IP's 2014 Intellectual Property Stars

Jeff Randall, Joseph O'Malley, Gerald Flattmann, Bruce Wexler, Melanie Rupert and Christopher Kennerly were named 2014 IP Stars by Managing Intellectual Property magazine. Nationwide, the firm's Intellectual Property practice was ranked in the Bio/Life Sciences, Copyright and Patent Contentious categories. In New York, the firm's IP practice was ranked Highly Recommended in the Patent Contentious category and in California, the IP practice was ranked Recommended in the Copyright and Patent Contentious categories.

April 29, 2014

Legal Media Group's 2013 LMG Life Science Awards
The firm was nominated as a 2013 LMG Life Science nominee in the “Litigation Team of the Year” and “(General) Patent Litigation: Firm of the Year” categories.
August 12, 2013

Legal Media Group's 2013 LMG Life Science Awards
Bruce Wexler was recognized by the Legal Media Group (LMG) as a 2013 LMG Life Science nominee for “Litigator of the Year.”
August 12, 2013

Intellectual Asset Management, IAM
Paul Hastings' New York and Nationwide IP practices were ranked in Intellectual Asset Management's IAM Patents 1000, a guide that identifies the top patent practitioners in key jurisdictions around the globe. Additionally, Joseph O'Malley, Jeff Randall, Matthew Berger (for Licensing), Gerald Flattmann, Allan Soobert and Bruce Wexler were singled out for distinction.
June 12, 2012

Intellectual Asset Management
Paul Hastings was recognized in Intellectual Asset Management's 2011 IAM 250: Patent Litigation survey. New York partners Joe O'Malley, Bruce Wexler and Gerald Flattmann were recognized individually in the patent litigation (overall) and life sciences categories. Palo Alto partner Jeff Randall was also recognized individually in the California patent litigation (overall) category.
May 01, 2011

Financial Times
"Standout" innovative lawyering in the handling of client Eisai's Aricept® patent litigation.
December 06, 2010

Intellectual Property Magazine
Intellectual Property Magazine recognized Paul Hastings' IP Pharmaceutical Team as the Pharmaceutical Team of the Year.
November 30, 2010

Professionals

Bruce M Wexler

Practice Areas

Admissions

Education

AWARDS AND ACCOLADES

Experience

Speaking Engagements and Publications

Professional and Community Involvement

Education

News

Insights

Upcoming Events

Rankings & Awards